SCHEMBL14720145

SCHEMBL14720145

CCc1n[nH]c(N)c1Cc1cccc(Cl)c1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNMT P11086 1/20 0.41
CCR2 P41597 1/20 0.41
CCR5 P51681 1/20 0.41
PTPN11 Q06124 1/20 0.38
TAAR1 Q96RJ0 1/20 0.38
PIK3CB P42338 3/20 0.38
PIK3CD O00329 2/20 0.38
PIK3CA P42336 2/20 0.38
PIK3CG P48736 1/20 0.38
IDO1 P14902 2/20 0.37
AR P10275 3/20 0.36
AKR1B1 P15121 1/20 0.36
NR3C1 P04150 1/20 0.36
RECQL P46063 1/20 0.34
MPO P05164 2/20 0.33
CHEK1 O14757 1/20 0.33
FLT3 P36888 1/20 0.33
PLK3 Q9H4B4 1/20 0.33
LMNA P02545 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14720127 0.83 PNMT (0.43) PNMTCCR2CCR5TAAR1PIK3CB
SCHEMBL14720422 0.82 PNMT (0.46) PNMTCCR2CCR5PTPN11TAAR1
SCHEMBL14720275 0.77 PNMT (0.40) PNMTCCR2CCR5TAAR1PIK3CB
SCHEMBL16992785 0.73 ALDH1A1 (0.40) TAAR1MPOLMNASMN1; SMN2
SCHEMBL14720231 0.71 PNMT (0.43) PNMTCCR2CCR5PTPN11TAAR1
SCHEMBL14720550 0.71 PIK3CD (0.43) PNMTCCR2CCR5PTPN11TAAR1
SCHEMBL13516129 0.71 SMN1; SMN2 (0.50) PNMTTAAR1ARMPOSMN1; SMN2
SCHEMBL5751697 0.71 CCR2 (0.37) CCR2CCR5IDO1LMNASMN1; SMN2
SCHEMBL14720179 0.69 PIK3CD (0.43) PNMTCCR2CCR5PTPN11TAAR1
SCHEMBL3341041 0.68 PNMT (0.46) PNMTCCR2CCR5PTPN11TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096605-B2 Pyrazolopyrimidine derivatives as PI3 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2015-08-04 US disclosed
US-9096605-B2 Pyrazolopyrimidine derivatives as PI3 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2015-08-04 US disclosed
US-9096605-B2 Pyrazolopyrimidine derivatives as PI3 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2015-08-04 US disclosed
US-20140187545-A1 Pyrazolopyrimidine Derivatives As PI3 Kinase Inhibitors GLAXOSMITHKLINE LLC (US) 2014-07-03 US disclosed
US-20140187545-A1 Pyrazolopyrimidine Derivatives As PI3 Kinase Inhibitors GLAXOSMITHKLINE LLC (US) 2014-07-03 US disclosed
US-20140187545-A1 Pyrazolopyrimidine Derivatives As PI3 Kinase Inhibitors GLAXOSMITHKLINE LLC (US) 2014-07-03 US disclosed
WO-2013028263-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-02-28 WO disclosed
WO-2013028263-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140187545-A1 Pyrazolopyrimidine Derivatives As PI3 Kinase Inhibitors PI4KB, PIK3CA, PI4K2B PNMT 4737/4885CCR2 4030/4885CCR5 4086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.